The present status and future directions of research and development on radionuclide generator technology are reported. The recent interest to develop double-neutron capture reactions for production of in vivo generators; neutron rich nuclides for radioimmunotherapeutic pharmaceuticals; and advances with ultrashort lived generators is highlighted. Emphasis is focused on: production of the parent radionuclide; the selection and the evaluation of support materials and eluents with respect to the resultant radiochemical yield of the daughter, and the breakthrough of the radionuclide parent; and, the uses of radionuclide generators in radiopharmaceutical chemistry, biomedical and industrial applications. The 62 Zn -62 Cu, ^Ni -""Cu, ,03m Rh -• ,03 Rh, ,88 W -• ,88 Re and the 225 Ac -22, Fr -2l3 Bi generators are predicted to be emphasized for future development.